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Abstract
Objectives N-terminal B-type natriuretic peptide (NT-
proBNP) is an important biomarker for the detection of
heart failure. Adults with congenital heart disease (ACHD)
and a prosthetic heart valve are at risk for heart failure.
This study aimed to determine the value of NT-proBNP in
ACHD patients with a prosthetic valve and investigate its
relationship with cardiac function and exercise capacity.
Methods In this multi-centre cross-sectional observational
study, data regarding medical history, echocardiography,
exercise testing (VO2peak) and laboratory blood evaluation
(including NT-proBNP) were collected in ACHD patients
with a single prosthetic valve (either homografts, hetero-
grafts or mechanical valves).
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Results A total of 306 ACHD patients with pulmonary
valve replacement (PVR, n = 139), aortic valve replacement
(n = 141), mitral valve replacement (n = 21) or tricuspid
valve replacement (n = 5) were investigated. The majority
of patients (77 %) were in NYHA class I or II. Elevated NT-
proBNP levels (cut-off ≥125 pg/ml) were found in 50 % of
the patients, with the highest levels in patients with mitral
valve replacements. In this study population, NT-proBNP
levels were associated with gender (p = 0.029) and VO2max
(p < 0.001). In PVR patients, NT-proBNP levels were
associated with lower VO2peak, also after adjustment for
age, gender and age at valve replacement in a multivariate
model (p = 0.015).
Conclusions In patients with ACHD and a prosthetic valve,
elevated NT-proBNP levels are frequently observed despite
preserved NYHA class. In PVR patients, a higher NT-
proBNP level was associated with a lower VO2peak. These
results may be of importance in the ongoing discussion
about the timing of valve replacement in patients with CHD.
Keywords Congenital heart disease · Pulmonary valve
replacement · NT-proBNP
Introduction
N-terminal B-type natriuretic peptide (NT-proBNP) is
a well-established marker of heart failure (HF) and a pre-
dictor of impaired cardiovascular prognosis [1]. The value
of NT-proBNP has been investigated in many patient popu-
lations, including patients with acute and chronic HF [2, 3]
and patients with valvular heart disease [4]. Remarkably,
data on NT-proBNP in adult patients with congenital heart
disease (ACHD) are scarce. A cross-sectional study among
patients with all types of ACHD showed that NT-proBNP
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Fig. 1 Flowchart of patient inclusion
Fig. 2 NT-proBNP: percentages elevated NT-proBNP (≥125 pg/ml)
and low NT-proBNP (<125 pg/ml) in different valve locations;
NT-proBNP N-terminal pro-brain natriuretic peptide, pg/ml
levels were elevated in a substantial but variable percentage
(26–88 %) [5], reflecting the heterogeneous nature of this
population. Therefore, to define its clinical utility, further
research is warranted among specific subgroups.
Within the diverse population of CHD patients, valve re-
placement surgery is often inevitable [6]. Recently, Diller
et al. [7]. demonstrated that especially those patients with
a history of valve replacement surgery are at risk for HF.
This may be related to the fact that prosthetic valves are
often implanted during childhood or adolescence, result-
ing in a probably higher prevalence of prosthesis patient
mismatch (PPM) than in non-congenital patients [8]. In
addition, also a watchful waiting strategy to allow children
and adolescents to grow further, in order to implant a larger
prosthetic valve, may result in valve-related HF and dete-
riorating functional class [9]. To what extent NT-proBNP
levels are of value for the clinical evaluation of ACHD pa-
tients with a prosthetic valve is unclear. Therefore, the aim
of this study was to investigate associations between NT-
proBNP and characteristics of valve prosthesis (including
PPM), ventricular function and exercise capacity in ACHD
patients with a prosthetic valve.
Methods
Patient population
In this multi-centre cross-sectional observational study,
named PROSTheses in Adult congenital heart VAlve dis-
ease (acronym: PROSTAVA), ACHD patients were selected
from the Dutch CONCOR registry [10]. The PROSTAVA
study was conducted to investigate the relationship be-
tween characteristics of valve prostheses (type, labelled
size, location) and functional outcome in ACHD patients.
Study design and rationale were previously described [11].
Briefly, patients with a prosthetic heart valve (homografts,
heterografts and mechanical valves in aortic, mitral, pul-
monary or tricuspid position) registered in the CONCOR
database and followed in one of the six PROSTAVA centres
were eligible. Patients with multiple prosthetic valves or
transposition of the great arteries with a systemic right
ventricle, either congenitally corrected or after Mustard/
Senning correction, were excluded. The study was con-
ducted in accordance with the Declaration of Helsinki and
was approved by the institutional ethics committees.
Collected data
Collected data concerned demography and medical history,
including previous cardiac surgical interventions, and were
obtained by reviewing patient records. Prospective data
were collected during routine clinical care: echocardiogra-
phy, exercise testing and laboratory blood tests (including
NT-proBNP and renal function).
NT-proBNP
Measurement of NT-proBNP was performed using the
Elecsys proBNP ELISA (Roche Diagnostics, Mannheim,
Germany). NT-proBNP was considered high when levels
were ≥125 pg/ml, based on the European Society of Cardi-
ology guidelines for non-acute presentation of heart failure
[12].
Echocardiography
Routine two-dimensional, M-mode and Doppler echocar-
diography were performed by experienced, board-certified
sonographers and supervised by cardiologists of the partic-
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Table 1 Baseline characteristics
Total (n = 306) AVR (n = 141) PVR (n = 139) MVR (n = 21) TVR (n = 5)
Male (%) 174 (57) 95 (67) 70 (50) 8 (38) 1 (20)
Diagnosis (%)
Tetralogy of Fallot – – 66 – –
Pulmonary atresia – – 12 – –
Pulmonary valve stenosis – – 12 – –
Bicuspid aortic valve – 49 – – –
(Sub)valvular aortic stenosis – 25 – – –
Marfan syndrome – 19 – – –
AVSD – – – 48 –
Mitral stenosis – – – 19 –
Ebstein malformation – – – – 100
Other – 71 102 333 –
Indication for valve replacement (%)
Regurgitation – 29 70 38 20
Stenosis – 21 13 14 –
Regurgitation and stenosis – 20 11 14 –
Other indications4 – 30 6 34 80
Age at first VR (y, SD) 27 ± 13 30 ± 11 24 ± 13 25 ± 17 19 ± 11
Age at last VR (y, SD) 30 ± 12 33 ± 11 26 ± 11 31 ± 13 29 ± 13
Time since last VR (y, SD) 9 ± 7 11 ± 8 8 ± 6 10 ± 6 3 ± 4
Number of valve replacements (%)
1 232 (76) 105 (74) 114 (82) 12 (57) 1 (20)
2 59 (19) 29 (21) 19 (14) 8 (38) 3 (60)
3 14 (5) 6 (4) 6 (4) 1 (5) 1 (20)
4 1 (0) 1 (1) 0 (0) 0 (0) 0 (0)
Valve type (%)
Biological 133 (43) 15 (11) 114 (82) 1 (5) 3 (60)
Bio conduit 5 (4) 0 (0) 5 (4) 0 (0) 0 (0)
Bio stented 111 (83) 7 (47) 101 (73) 1 (100) 2 (67)
Bio stentless 11 (8) 8 (53) 3 (2) 0 (0) 0 (0)
Transcatheter 7 (5) 0 (0) 6 (4) 0 (0) 1 (33)
Mechanical 170 (56) 126 (89) 22 (16) 20 (95) 2 (40)
Bi-leaflet 154 (90) 113 (90) 22 (100) 17 (85) 2 (100)
Mono-leaflet 16 (9) 13 (10) 0 (0) 3 (15) 0 (0)
Valve size 25 ± 3 23 ± 3 25 ± 2 29 ± 3 31 ± 4
Age (y, SD) 39 ± 11 44 ± 11 35 ± 10 41 ± 13 32 ± 13
Body surface area (SD) 1.95 ± 0.2 1.99 ± 0.2 1.92 ± 0.2 1.87 ± 0.2 1.87 ± 0.3
BMI (SD) 24.7 ± 4 25.1 ± 4 24.2 ± 4 24.7 ± 4 27.5 ± 4
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Table 1 Baseline characteristics (Continued)
Total (n = 306) AVR (n = 141) PVR (n = 139) MVR (n = 21) TVR (n = 5)
NYHA (%)
I 148 (48) 82 (58) 65 (47) 1 (5) 0 (0)
II 86 (28) 41 (29) 42 (30) 3 (14) 0 (0)
III 42 (14) 10 (7) 12 (9) 15 (71) 5 (100)
IV 4 (1) 0 (0) 2 (1) 2 (10) 0 (0)
Unknown 26 (9) 8 (6) 18 (13) 0 (0) 0 (0)
1 Truncus arteriosus (2.9); atrial septal defect + D.B. (0.7); ventricular septal defect (VSD) (0.7); double outlet right ventricle (DORV) Fallot (0.7);
DORV transposition of the great arteries (TGA) (0.7); TGA + pulmonary stenosis + VSD (2.2); empty cells (2.2).
2VSD + coarctation (3.6); TGA (1.4); PA + VSD (0.7).
3Anomalous left coronary artery arising from the pulmonary artery (ALCAPA) (4.8); ASD (21.3); DORV + coarctation (4.8); Marfan (4.8);
bicuspid aortic valve + coarctation (4.8).
4 Other indications include valve atresia, aorta dissection, aortic dilatation, endocarditis and valve complications. Values are mean/median ±
standard deviation (SD); AVR aortic valve replacement, PVR pulmonary valve replacement, MVR mitral valve replacement, TVR tricuspid valve
replacement, VR valve replacement, AVSD atrioventricular septal defect, VSD ventricular septal defect, TGA transposition of the great arteries,
PA patent arteriosus, ToF Tetralogy of Fallot, ASD atrial septal defect, DORV (Fallot) double outlet right ventricle (ToF), ALCAPA anomalous left
coronary artery arising from the pulmonary artery, NYHA New York Heart Association, y years.
Table 2 Echocardiography, exercise capacity and NT-proBNP
Method Variable Total AVR PVR MVR TVR
n (%) 306 (100) 141 (46) 139 (45) 21 (7) 5 (2)
Echocardiography LVEF (%) 55 ± 8 57 ± 9 55 ± 6 50 ± 11 –
LVEF ≥50 % (n, %) 108 (77) 35 (78) 70 (78) 3 (60) –
LVEDD (mm) 50 ± 8 50 ± 7 49 ± 8 53 ± 10 48 ± 7
LVESD (mm) 34 ± 8 33 ± 7 34 ± 7 41 ± 9 28 ± 7
LV mass (g/m2 BSA) 97 ± 33 98 ± 29 60 ± 54 112 ± 40 80 ± 28
TAPSE (mm) 17 ± 4 17 ± 4 17 ± 4 18 ± 3 15 ± 3
TAPSE ≥17 mm (n, %) 150 (56) 59 (54) 75 (57) 14 (70) 2 (40)
EOA (cm2/m2) 2.1 ± 1 1.9 ± 1 2.4 ± 2 2.4 ± 1 4.9
Exercise testing VO2peak (ml/min/kg) 27 ± 8 29 ± 8 28 ± 7 22 ± 7 19 ± 6
PPEC (%) 81 ± 23 84 ± 24 76 ± 19 72 ± 25 71 ± 34
PPEC 75 % (n, %) 94 (41) 32 (31) 48 (47) 12 (67) 2 (50)
Laboratory blood NT-proBNP 140 ± 329 146 ± 374 108 ± 253 316 ± 372 247 ± 300
% High NT-proBNP 52 54 44 86 80
Values are mean or median ±SD or n. LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic diameter, LVESD left ven-
tricular end-systolic diameter, RVEF right ventricular ejection fraction, TAPSE tricuspid annular plane systolic excursion, EOA effective orifice
area, PPEC percentage of predicted exercise capacity, NT-proBNP N-terminal pro-brain natriuretic peptide, pg/ml (cut-off for high NT-proBNP
≥125 pg/ml)
ipating hospital. Both the images and reports were sent
to the University Medical Center Groningen, where the
echocardiograms were blinded. Measurements related to
the prosthetic valve were independently re-assessed and
subsequently checked by senior investigators.
Other measurements concerning ventricular size and
function and native valve morphology and function were
collected from the original echo reports. Left ventricular
ejection fraction (LVEF) was measured using Simpson’s
rule or, when image quality was suboptimal, using vi-
sual estimation. Right ventricular function was assessed
with tricuspid annular plane systolic excursion (TAPSE).
Prosthetic valvar effective orifice area (EOA in cm2) was
calculated using the continuity equation [13]. EOA was
indexed for body surface area (iEOA). For aortic valve
replacement (AVR) patients, PPM was classified as mod-
erate PPM (iEOA 0.85–0.65 cm2/m2) and as severe PPM
(iEOA <0.65 cm2/m2) [8]. The native pulmonary EOA in
adults is about 30 % larger than the aortic EOA [14]. We
therefore assumed cut-off values for PPM in pulmonary
valve replacement (PVR) patients accordingly (moderate
PPM was defined as iEOA 1.10 cm2/m2 and severe PPM
as iEOA 0.85 cm2/m2).
Exercise capacity testing
Exercise capacity was measured using a bicycle or treadmill
ergometer, assessing either peak oxygen uptake (VO2peak,
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Table 3 Univariable and multivariable parameters associated with NT-proBNP for all patients (cut-off 125 pg/ml)
Univariate Multivariate
All All
Variable 95 % CI (B) p 95 % CI (B) p
BSA (m2) –0.50 to 0.07 0.141 – –
BMI (kg/m2) –0.01 to 0.02 0.545 – –
Gender –0.41 to –0.15 >0.001 –0.34 to –0.02 0.029
Age 0.01 to 0.02 >0.001 –0.01 to 0.02 0.310
NYHA class –0.01 to 0.16 0.077 –0.08 to 0.11 0.804
Age at first VR (y) 0.00 to 0.01 0.164 – –
Age at last VR (y) 0.00 to 0.01 0.020 –0.02 to 0.01 0.295*
Time since last VR (y) 0.00 to 0.02 0.093 – –
Valve size (mm) 0.01 to 0.03 0.434 – –
Valve type (bio/mech) 0.00 to 0.27 0.055 –0.07 to 0.25 0.257
iEOA (cm2/m2) –0.18 to 0.12 0.689 – –
PPM (iEOA 0.85 cm2/m2) –0.21 to 0.11 0.520 – –
Indexed LV mass (g/m2) 0.00 to 0.00 0.313 – –
LVEF (%) –0.01 to 0.01 0.939 – –
LVEDD (mm) –0.01 to 0.01 0.402 – –
LVESD (mm) 0.00 to 0.02 0.184 – –
RVEF (%) –0.01 to 0.02 0.371 – –
TAPSE (mm) –0.02 to 0.02 0.808 – –
Renal function (ml/min) –0.01 to 0.00 0.022 –0.01 to 0.00 0.107
VO2max (ml/min/kg) –0.03 to –0.02 <0.001 –0.03 to –0.01 <0.001
PPEC (%) –0.01 to 0.00 0.113 – –
CI confidence interval, BSA body surface area, BMI body mass index, VR valve replacement, iEOA indexed effective orifice area, PPM patient
prosthesis mismatch, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic
diameter, RVEF right ventricular ejection fraction, TAPSE tricuspid annular plane systolic excursion, PPEC percentage of predicted exercise
capacity, np not performed. Bold text: univariable parameters with a p-value <0.1 are used in multivariate regression analysis. *Collinearity of
Statistics is reported between the variables ‘age at last VR’ and ‘time since last VR’
ml/min/kg) or maximum workload (Wpeak, Watts). The
predicted peak oxygen uptake (VO2pred) and workload
(Wpred) was calculated as previously described [15, 16].
Exercise capacity testing was performed uniformly and
reproducible among the different centres and started with
a short warm-up (without load), followed by a stepwise in-
crease of workload consistent with a protocol based on sex,
age, height and weight. Exercise duration was aimed for at
least 6–8 minutes. The percentage of predicted exercise ca-
pacity (PPEC) was calculated by dividing the achieved ex-
ercise level (VO2peak or Wpeak) by the predicted exercise
level (VO2pred or Wpred). A PPEC 75 % was considered
a decreased exercise capacity [17].
Statistics
Data were analysed using SPSS® Statistics version 22.0.
Descriptive statistics were calculated as mean values and
standard deviations for normally distributed continuous
variables, medians and quartiles for continuous variables
with non-normal distribution and absolute numbers and
percentages for dichotomous variables. Comparisons of
continuous variables between groups were made by un-
paired Student’s t-tests or the Mann-Whitney U test, de-
pending on their distribution, and dichotomous variables
were compared using the χ2 or Fisher’s exact test. Uni-
variable and multivariable regression analysis (dependent
variable: NT-proBNP) was used to study the association
between NT-proBNP and prosthetic valve characteristics
or functional capacity. All independent covariates with
p < 0.10 in univariable regression analyses were included
in multivariable regression analysis. A two-sided p-value
<0.05 was considered statistically significant. Due to the
limited number of patients with mitral valve replacement
(MVR) and tricuspid valve replacement (TVR), regression
analyses were confined to AVR and PVR patients.
Results
A flowchart for patient selection with exclusion criteria is
shown in Fig. 1. The study population comprised 141 AVR
patients, 139 PVR patients, 21 MVR patients and 5 TVR
patients. Baseline characteristics are presented in Table 1.
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Fig. 3 Association between NT-proBNP (cut-off 125 pg/ml) and
VO2peak in PVR patients; NT-proBNP N-terminal pro-brain natri-
uretic peptide, pg/ml (cut-off for high NT-proBNP ≥125 pg/ml),
PVR pulmonary valve replacement. Dotted line indicates cut-off for
elevated NT-proBNP levels (125 pg/ml). Pearson’s r = –0.555, p <
0.001, y = 33 – 0.03*x
The majority were male (57 %). The main diagnosis in
PVR patients was Tetralogy of Fallot (ToF, 66 %) and in
AVR patients bicuspid aortic valve (49 %).
Mean age at surgery for first and latest valve replace-
ment was 27 ± 13 (range 0–51) and 30 ± 12 years (range
3–67), respectively. The valve type differed between AVR
and PVR patients: 89 % of AVR were mechanical valves
while in PVR 82 % of the patients had biological valves
implanted (p < 0.001). The majority of patients were in
NYHA class I–II at inclusion (76 %). NYHA class was
significantly higher in MVR patients compared with PVR
and AVR patients (p < 0.001). Age at first and last valve
replacement was significantly higher in AVR patients com-
pared with PVR patients (p < 0.001).
NT-proBNP
The median NT-proBNP level in the total study population
was 140 (range 13–3132) pg/ml (Table 2). Patients with
higher NT-proBNP levels were more likely to be women
(median level 183 and 104 pg/ml in women and men, re-
spectively, p < 0.001) and older (p < 0.001). For the
whole study sample, higher age at latest valve replacement
was significantly associated with higher NT-proBNP levels
(p = 0.02). Median NT-proBNP level in AVR patients was
146 pg/ml, compared with 108 pg/ml in PVR patients (p =
ns). The highest NT-proBNP levels were seen in MVR
patients (median 316 pg/ml; p < 0.001 and p = 0.002 com-
pared with PVR and AVR, respectively). High NT-proBNP
levels (≥125 pg/ml) were found in 44 % of the PVR pa-
tients, 54 % of the AVR patients, and 86 and 80 % of the
MVR and TVR patients, respectively (Fig. 2).
Echocardiography and exercise testing
Echocardiographic characteristics of the entire study pop-
ulation and for each separate prosthetic valve location are
displayed in Table 2. Normal LVEF was found in 78 % of
the AVR patients and 78 % of the PVR patients. Left ven-
tricular (LV) mass was higher in AVR in comparison with
PVR patients (p = 0.015).
A normal right ventricular function (TAPSE ≥17 mm)
was found in 56.4 % (n = 150) of all patients, including
57.3 % of PVR patients (n = 75) and 53.6 % of AVR patients
(n = 59). The effective orifice area (EOA) of the pulmonary
valves was significantly larger than aortic prosthetic valves
(Table 2, p = 0.003). PPM was found in 50 % of the PVR
patients and 48 % of the AVR patients.
Exercise capacity was assessed in 228 patients (75 %),
with 194 VO2max tests (85 %) and 34 ergometric tests
(15 %). In all patients, the median PPEC was 81 % (IQR
65–98 %) and 41 % had impaired exercise capacity (PPEC
75 %, Table 2). Decreased PPEC was observed in 31 % of
the AVR patients, compared with 47 % of the PVR patients
(p = 0.017). VO2peak was significantly lower in MVR com-
pared with AVR (p = 0.001) and PVR patients (p < 0.001).
Associations with high NT-proBNP levels (≥125 pg/ml)
For the entire study population, gender (p < 0.001), age
(p < 0.001), age at last valve replacement (p = 0.020),
renal function (p = 0.022) and VO2max (p < 0.001) were
associated with NT-proBNP (p < 0.05). Gender (p = 0.029)
and VO2max (p < 0.001) were associated with NT-proBNP
in multivariate analysis as well (Table 3).
In the PVR group, univariable parameters associated
with NT-proBNP (p < 0.1) included age at valve replace-
ment surgery (p = 0.091) and VO2peak (p < 0.001) (Table 4;
Fig. 3). In a multivariate model, a higher NT-proBNP level
remained significantly associated with a lower VO2peak,
even after adjustment for age, gender and age at valve re-
placement surgery (p = 0.015), as presented in Table 4.
PPEC was negatively associated with NT-proBNP as well
(p = 0.025 in PVR) when corrected for the same variables.
In AVR patients, VO2peak was negatively associated
with NT-proBNP as well, although in a multivariable
model, including age, gender and renal function, only
gender remained significantly associated with NT-proBNP
(p = 0.034, Table 4).
Discussion
This multi-centre cross-sectional study focused on the value
of NT-proBNP in ACHD and a prosthetic valve. Using
the European Society of Cardiology cut-off for chronic HF
Houten 2016
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Table 4 Univariable and multivariable parameters associated with NT-proBNP for PVR and AVR patients (cut-off 125 pg/ml)
Univariate Multivariate
PVR AVR PVR AVR
Variable 95 % CI (B) P 95 % CI (B) P 95 % CI (B) P 95 % CI (B) P
BSA (m2) –0.59 to 0.27 0.460 –0.76 to 0.10 0.128 – – – –
BMI (kg/m2) –0.02 to 0.02 0.990 –0.03 to 0.03 0.877 – – – –
Gender –0.47 to
–0.08
0.007 –0.52 to
–0.14
0.001 –0.43 to
–0.01
0.045 –0.57 to
–0.02
0.034
Age 0.01 to 0.03 0.004 0.00 to 0.02 0.047 –0.00 to 0.05 0.098 –0.01 to 0.01 0.951
NYHA class –0.10 to 0.18 0.582 –0.13 to 0.18 0.769 – – – –
Age at first VR (y) –0.00 to 0.01 0.119 –0.01 to 0.01 0.710 – – – –
Age at last VR (y) –0.00 to 0.02 0.091 –0.00 to 0.01 0.247 –0.03 to 0.01 0.251 – –
Time since last VR
(y)
–0.01 to 0.03 0.174 –0.01 to 0.02 0.258 – – – –
Valve size (mm) –0.04 to 0.05 0.811 –0.06 to 0.01 0.172 – – – –
Valve type (bio/
mech)
–0.15 to 0.36 0.397 –0.32 to 0.41 0.802 – – – –
iEOA (cm2/m2) –0.22 to 0.19 0.882 –0.37 to 0.19 0.523 – – – –
PPM (iEOA
0.85 cm2/m2)
–0.10 to 0.44 0.204 –0.23 to 0.18 0.816 – – – –
Indexed LV mass
(g/m2)
Np Np –0.00 to 0.01 0.217 – – – –
LVEF (%) –0.01 to 0.02 0.503 –0.03 to 0.01 0.440 – – – –
LVEDD (mm) –0.03 to 0.01 0.217 –0.01 to 0.02 0.250 – – – –
LVESD (mm) –0.02 to 0.02 0.735 –0.01 to 0.02 0.421 – – – –
RVEF (%) –0.01 to 0.02 0.666 –0.01 to 0.02 0.641 – – – –
TAPSE (mm) –0.03 to 0.02 0.859 –0.03 to 0.03 0.912 – – – –
Renal function
(ml/min)
–0.01 to 0.00 0.248 –0.01 to
–0.00
0.009 – – –0.01 to 0.00 0.087
VO2max
(ml/min/kg)
–0.04 to
–0.02
<0.001 –0.03 to
–0.00
0.042 –0.04 to
–0.00
0.015 –0.02 to 0.01 0.698
PPEC (%) –0.01 to 0.00 0.245 –0.01 to 0.00 0.922 – – – –
AVR aortic valve replacement, PVR pulmonary valve replacement, CI confidence interval, BSA body surface area, BMI body mass index, VR valve
replacement, iEOA indexed effective orifice area, PPM patient prosthesis mismatch, LVEF left ventricular ejection fraction, LVEDD left ventricular
end-diastolic diameter, LVESD left ventricular end-systolic diameter, RVEF right ventricular ejection fraction, TAPSE tricuspid annular plane
systolic excursion, PPEC percentage of predicted exercise capacity, np not performed. Bold text: univariable parameters with a p-value <0.1 are
used in multivariate regression analysis
of 125 pg/ml, elevated NT-proBNP levels were found in
more than 50 % of the patients. In PVR patients, high
NT-proBNP levels were associated with decreased exercise
capacity.
NT-proBNP in CHD
The high percentage of elevated NT-proBNP levels in PVR
patients and AVR patients (44 and 54 %, respectively) is
remarkable. In a smaller subgroup of patients with an
atrioventricular prosthetic valve, this percentage was even
higher (i. e. 86 % for MVR and 80 % for TVR patients).
The high percentages of elevated NT-proBNP levels in our
ACHD population are comparable to, for example, popula-
tions with stable chronic kidney disease (127 vs. 140 pg/ml
in this population) [18], but not as high as recently re-
ported in a population with HF with preserved ejection
fraction (median 1772 pg/ml) [19]. For ACHD patients,
Eindhoven et al. found comparable percentages of elevated
NT-proBNP levels in both a heterogeneous group with vari-
ous ACHD patients [5] and in adult patients with corrected
ToF (53 and 55 %, respectively) [20]. However, in their
study population with various CHD lesions, patients with
systemic right ventricular and Fontan circulation mainly
contributed to the elevated NT-proBNP levels. In our study,
these patients were excluded.
The higher NT-proBNP levels found in AVR patients
compared with PVR patients (146 vs. 108 pg/ml, respec-
tively) could possibly be explained by the higher LV mass
found in AVR patients (p = 0.015). The study by Mishra
et al. [18]. in patients with chronic kidney disease de-
scribes the association between high NT-proBNP levels and
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higher LV mass. However, this association between high
NT-proBNP levels and LV mass in AVR patients did not
hold true in the regression analysis.
Whether the high percentages of elevated NT-proBNP in
our study cohort are related to surgical technique, prosthetic
valve material, (subclinical) heart failure or the timing of
valve surgery could not be answered by this study. Serial
measurements could shed light on this interesting question.
Associations with high NT-proBNP levels (≥125 pg/ml)
In line with other studies, NT-proBNP levels were higher in
women and associated with ageing [21]. This finding high-
lights the need for sex- and age-specific reference values of
NT-proBNP to be useful for diagnostic purposes.
Although NT-proBNP levels tended to be related to the
age at last valve replacement, indicating that higher age at
last valve replacement may possibly result in higher NT-
proBNP levels at adult age, this association did not hold
true after adjustment for sex and age. At least in our pop-
ulation, this may indicate that high pro-BNP levels are not
a reflection of a late valve replacement. Given the rela-
tionship between ventricular dysfunction and HF, it may be
anticipated that ventricular function is associated with NT-
proBNP levels. Yet, we did not find such a relationship.
However, diastolic characteristics (not taken into account
in our study) are also of importance in the release of NT-
proBNP, as recently described for a CHD population [22].
Although we previously found an association between PPM
and exercise capacity in AVR patients [23], this did not
translate into higher NT-proBNP levels in this subgroup.
At least for AVR patients, a possible explanation could be
the rather preserved left ventricular systolic function (mean
LVEF 57 %).
NT-proBNP and exercise capacity in PVR patients
We found an association between NT-proBNP and exer-
cise capacity in PVR patients: a higher NT-proBNP level
was associated with a lower VO2peak. This result is in
line with the findings in patients with various CHD lesions
(with or without prosthetic valve) of Eindhoven et al. [5].
Of note, Eindhoven et al. could not establish this associa-
tion in their population of adult ToF patients [20]; however
in their study only 55 % of the ToF patients had a pros-
thetic valve, whereas our findings were most profound in
PVR patients, of which 66 % were diagnosed with ToF. Our
results are in line with those of Norozi et al. who found
a correlation between exercise capacity and NT-proBNP in
ToF patients, also showing comparable NT-proBNP levels
as found in our study [24]. Our findings strengthen the
use of NT-proBNP as possible marker of functional capac-
ity in PVR patients. Although right ventricular function
is an important determinant of exercise performance [25],
we could not confirm significant associations between NT-
proBNP and TAPSE. However, one has to keep in mind that
TAPSE reflects only longitudinal right ventricular contrac-
tion, whereas radial contraction may be preserved or even
enhanced postoperatively. This finding is reinforced by the
fact that in AVR patients TAPSE was decreased in a similar
proportion (46 % vs. 43 % in PVR patients, p = ns).
Limitations
The multiple types and locations of the prosthetic valves
in combination with the underlying cardiac malformation
resulted in a heterogeneous population. We chose to analyse
our data separately for each valve location. Therefore, the
study results that were found in PVR patients could not
be extrapolated to patients with another located prosthetic
valve (or vice versa). Finally, due to the limited number of
patients, MVR and TVR patients were not included in the
regression analysis.
Conclusion
NT-proBNP levels are elevated in more than 50 % of the
ACHD population with a prosthetic valve. Higher NT-
proBNP levels are strongly associated with poor exercise
capacity in PVR patients. Further, prospective studies of
NT-proBNP values in CHD patients are necessary in order
to assess its predictive value for prognosis in these patients.
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